Consequently, the disruption of functional interaction between ERα and PI3K, using the combination of Src or PI3K inhibitors plus tamoxifen or fulvestrant, has been proposed as a strategy in the treatment of ERα+ breast cancer (64, 65). Here, SRC is linked to breast cancer.